Debt-to-equity of Coherus Oncology, Inc. from 30 Jun 2015 to 30 Sep 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Coherus Oncology, Inc. quarterly Debt-to-equity in % history and change rate from 30 Jun 2015 to 30 Sep 2025.
Coherus Oncology, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was -1746%, a 159% decline year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

Coherus Oncology, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q3 2025	-1746%	-1071%	-159%	30 Sep 2025
Q2 2025	-722%	-84%	-13%	30 Jun 2025
Q1 2025	-510%	+9.1%	+1.7%	31 Mar 2025
Q4 2024	-720%	-321%	-81%	31 Dec 2024
Q3 2024	-675%	-274%	-68%	30 Sep 2024
Q2 2024	-638%	-224%	-54%	30 Jun 2024
Q1 2024	-519%	+17%	+3.2%	31 Mar 2024
Q4 2023	-399%	+589%	+60%	31 Dec 2023
Q3 2023	-402%	+24713%	+98%	30 Sep 2023
Q2 2023	-414%	-1487%	-139%	30 Jun 2023
Q1 2023	-536%	-1130%	-190%	31 Mar 2023
Q4 2022	-988%	-1445%	-316%	31 Dec 2022
Q3 2022	-25115%	-25448%	-7628%	30 Sep 2022
Q2 2022	1072%	+797%	+290%	30 Jun 2022
Q1 2022	593%	+341%	+135%	31 Mar 2022
Q4 2021	457%	+241%	+111%	31 Dec 2021
Q3 2021	334%	+101%	+43%	30 Sep 2021
Q2 2021	275%			30 Jun 2021
Q1 2021	253%			31 Mar 2021
Q4 2020	216%			31 Dec 2020
Q3 2020	233%			30 Sep 2020
Q4 2018	1493%	+1209%	+426%	31 Dec 2018
Q3 2018	498%	+184%	+59%	30 Sep 2018
Q2 2018	354%	-19%	-5.1%	30 Jun 2018
Q1 2018	461%	-647%	-58%	31 Mar 2018
Q4 2017	284%	+1543%		31 Dec 2017
Q3 2017	313%	+1297%		30 Sep 2017
Q2 2017	374%	+1441%		30 Jun 2017
Q1 2017	1108%	-163%	-13%	31 Mar 2017
Q4 2016	-1260%	-1644%	-428%	31 Dec 2016
Q3 2016	-984%	-1211%	-533%	30 Sep 2016
Q2 2016	-1067%	-2088%	-205%	30 Jun 2016
Q1 2016	1272%			31 Mar 2016
Q4 2015	384%			31 Dec 2015
Q3 2015	227%			30 Sep 2015
Q2 2015	1020%			30 Jun 2015

* An asterisk sign (*) next to the value indicates that the value is likely invalid.